Spots Global Cancer Trial Database for aplastic anemia
Every month we try and update this database with for aplastic anemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients | NCT03318159 | Aplastic Anemia Myelodysplastic... Fungal Infectio... | Posaconazole | 18 Years - 75 Years | Seoul National University Hospital | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) | NCT01191749 | Leukemia | Alemtuzumab | - | M.D. Anderson Cancer Center | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients | NCT03318159 | Aplastic Anemia Myelodysplastic... Fungal Infectio... | Posaconazole | 18 Years - 75 Years | Seoul National University Hospital | |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02566304 | Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| National Longitudinal Cohort of Hematological Diseases | NCT04645199 | Multiple Myelom... Myeloma, Multip... Myelomas, Multi... Acute Myeloid L... Leukemias, Acut... Myeloid Leukemi... Hemophilia Hemophilia A Hemophilia As Hemophilia B Hemophilia Bs Myelodysplastic... MDS Lymphoma Leukemia Aplastic Anemia Bleeding Disord... Bone Marrow Tra... Blood Disease I... | - | Institute of Hematology & Blood Diseases Hospital, China | ||
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | NCT06303193 | Myelodysplastic... | pacritinib | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | NCT04439006 | Aplastic Anemia Hematopoietic a... Malignant Solid... Monoclonal B-Ce... Monoclonal Gamm... Myelodysplastic... Symptomatic COV... | Best Practice Ibrutinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients | NCT01343680 | Childhood Cance... Aplastic Anemia Metabolic Disor... | Heparin Normal saline | - 17 Years | Alberta Children's Hospital | |
| Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors | NCT05194397 | Lymphoblastic L... Cancer Survivor... Aplastic Anemia Myelodysplastic... | Nicotinamide Ri... Placebo Exercise Interv... | 10 Years - 30 Years | Children's Hospital of Philadelphia | |
| TPO-Mimetic Use in Children for Hematopoietic Failure | NCT04478227 | Bone Marrow Fai... Aplastic Anemia Thrombocytopeni... Refractory Cyto... Myelodysplastic... | Romiplostim | 0 Years - 21 Years | University of Iowa | |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | NCT05972577 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myeloge... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... | Health Promotio... Medical Device ... Quality-of-Life... Questionnaire A... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure | NCT00895739 | Nonmalignant Ne... | alemtuzumab cyclosporine | 18 Years - | National Cancer Institute (NCI) | |
| Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results | NCT04060485 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Aplastic Anemia | 18 Years - 120 Years | National Taiwan University Hospital | ||
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination | NCT02007811 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Non Hodgkin's L... Hodgkin's Disea... Myelodysplastic... Multiple Myelom... Aplastic Anemia | allogeneic dono... | 18 Years - 75 Years | University of Erlangen-Nürnberg Medical School | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | NCT03176849 | Vitamin D Defic... Stem Cell Trans... Pediatric Cance... Blood Disorder Pediatric Acute... Pediatric Acute... Myelodysplastic... Sickle Cell Ane... Aplastic Anemia Thalassemia in ... | Vitamin D3 Standard Vitami... | 1 Year - 25 Years | Phoenix Children's Hospital | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| Reduced Intensity Double Umbilical Cord Blood Transplantation | NCT01408563 | Non-Hodgkin's L... Hodgkin's Lymph... Multiple Myelom... Chronic Lymphoc... Acute Myelogeno... | Fludarabine Melphalan Total Body Radi... Cord Blood | 18 Years - 70 Years | Massachusetts General Hospital | |
| Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | NCT01350245 | Acute Myeloid L... Myelodysplastic... Biphenotypic Le... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Plasma Cell Neo... Lymphoma Hodgkin's Disea... Aplastic Anemia | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Mycophenolate M... Tacrolimus Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| King's Invasive Aspergillosis Study II | NCT02875743 | Aplastic Anemia Leukemia, Myelo... Myelodysplastic... Bone Marrow Tra... | Posaconazole | 18 Years - | King's College Hospital NHS Trust | |
| Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study | NCT03086252 | Anemia Aplastic Anemia Bone Marrow Fai... Hematopoietic a... Leukemia Myelodysplastic... | Red Blood Cell ... | 19 Years - | Emory University | |
| Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome | NCT01624805 | Aplastic Anemia de Novo Myelody... Myelodysplastic... Previously Trea... | Anti-Thymocyte ... Cyclosporine Filgrastim Methylprednisol... Pegfilgrastim | 18 Years - | M.D. Anderson Cancer Center | |
| Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome | NCT02462252 | Aplastic Anemia Hypoplastic Mye... | BL-8040 horse anti-thym... Methylprednisol... Cyclosporine | 18 Years - | BioLineRx, Ltd. | |
| A Phase II Study of Umbilical Cord Blood Transplantation | NCT00676806 | Leukemia Lymphoma Multiple Myelom... Aplastic Anemia | Umbilical Cord ... Umbilical Cord ... | - 70 Years | Tufts Medical Center | |
| A Phase II Study of Umbilical Cord Blood Transplantation | NCT00676806 | Leukemia Lymphoma Multiple Myelom... Aplastic Anemia | Umbilical Cord ... Umbilical Cord ... | - 70 Years | Tufts Medical Center | |
| Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | NCT04439006 | Aplastic Anemia Hematopoietic a... Malignant Solid... Monoclonal B-Ce... Monoclonal Gamm... Myelodysplastic... Symptomatic COV... | Best Practice Ibrutinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02566304 | Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome | NCT00806598 | Myelodysplastic... Aplastic Anemia | Thymoglobulin Cyclosporine Methylprednisol... G-CSF | 15 Years - | M.D. Anderson Cancer Center | |
| Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome | NCT01624805 | Aplastic Anemia de Novo Myelody... Myelodysplastic... Previously Trea... | Anti-Thymocyte ... Cyclosporine Filgrastim Methylprednisol... Pegfilgrastim | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Emapalumab for Pediatric Aplastic Anemia | NCT06430788 | Aplastic Anemia Cytopenia Hypocellular Ma... | Emapalumab | 0 Years - 25 Years | Memorial Sloan Kettering Cancer Center | |
| Umbilical Cord Blood Transplantation From Unrelated Donors | NCT03016806 | Acute Leukemia Immune Deficien... Congenital Hema... Metabolism Diso... Aplastic Anemia Myelodysplastic... Chronic Leukemi... Lymphoma Multiple Myelom... Solid Tumor | Total Body Irra... Total Body Irra... Cyclophosphamid... Mesna Cord Blood Infu... Busulfan Fludarabine Melphalan | 2 Months - 75 Years | University of Rochester | |
| Nonmyeloablative Allogeneic Transplant | NCT01272817 | Aplastic Anemia Paroxysmal Noct... Acute Myelogeno... Acute Lymphocyt... Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Hodgkin's Lymph... Non-Hodgkin's L... Mantle Cell Lym... Multiple Myelom... Waldenstrom Mac... Breast Cancer Renal Cell Carc... Melanoma Sarcoma Ovarian Cancer Thymoma | Nonmyeloablativ... Nonmyeloablativ... | 18 Years - 72 Years | Scripps Health | |
| Reduced Intensity Double Umbilical Cord Blood Transplantation | NCT01408563 | Non-Hodgkin's L... Hodgkin's Lymph... Multiple Myelom... Chronic Lymphoc... Acute Myelogeno... | Fludarabine Melphalan Total Body Radi... Cord Blood | 18 Years - 70 Years | Massachusetts General Hospital | |
| Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology | NCT06335277 | Leukemia Leukemia, Chron... Leukemia, Acute Lymphoma Aplastic Anemia | 18 Years - | European Institute of Oncology | ||
| Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant | NCT00510315 | Leukemia Hodgkin's Lymph... Non-Hodgkin's L... Myelodysplastic... | Questionnaires,... | 18 Years - 49 Years | Memorial Sloan Kettering Cancer Center | |
| Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome | NCT00731328 | Leukemia Myelodysplastic... Nonmalignant Ne... Paroxysmal Noct... | nonmyeloablativ... | - 75 Years | Asan Medical Center | |
| Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | NCT00513175 | Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Lymphoc... Follicular Lymp... Multiple Myelom... NHL Myeloproliferat... Chronic Myeloid... Renal Cell Carc... Aplastic Anemia | 16 Years - 75 Years | University of California, San Francisco | ||
| Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients | NCT01343680 | Childhood Cance... Aplastic Anemia Metabolic Disor... | Heparin Normal saline | - 17 Years | Alberta Children's Hospital | |
| Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) | NCT01191749 | Leukemia | Alemtuzumab | - | M.D. Anderson Cancer Center | |
| Investigation of the Cylex® ImmuKnow® Assay | NCT00569842 | Leukemia Non-Hodgkin's L... Chronic Lymphoc... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... Aplastic Anemia Chronic Myeloge... | 18 Years - | Indiana University | ||
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02566304 | Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | NCT01500161 | Acute Myelogeno... Acute Lymphocyt... Chronic Lymphoc... Chronic Myeloge... Hodgkins Diseas... Non-Hodgkins Ly... Aplastic Anemia Multiple Myelom... Myelodysplastic... | Busulfan Clofarabine Fludarabine Melphalan Carmustine Etoposide Cytarabine | 18 Years - 65 Years | Texas Oncology Cancer Center | |
| A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | NCT03176849 | Vitamin D Defic... Stem Cell Trans... Pediatric Cance... Blood Disorder Pediatric Acute... Pediatric Acute... Myelodysplastic... Sickle Cell Ane... Aplastic Anemia Thalassemia in ... | Vitamin D3 Standard Vitami... | 1 Year - 25 Years | Phoenix Children's Hospital | |
| Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | NCT03622788 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Bone Marrow Fai... Chronic Lymphoc... Chronic Myeloge... Follicular Lymp... Hodgkin Lymphom... Mantle Cell Lym... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... | Anti-Thymocyte ... Cyclophosphamid... Cytokine-treate... Fludarabine Peripheral Bloo... Total-Body Irra... | 12 Years - 75 Years | M.D. Anderson Cancer Center | |
| King's Invasive Aspergillosis Study II | NCT02875743 | Aplastic Anemia Leukemia, Myelo... Myelodysplastic... Bone Marrow Tra... | Posaconazole | 18 Years - | King's College Hospital NHS Trust | |
| Umbilical Cord Blood Transplantation From Unrelated Donors | NCT03016806 | Acute Leukemia Immune Deficien... Congenital Hema... Metabolism Diso... Aplastic Anemia Myelodysplastic... Chronic Leukemi... Lymphoma Multiple Myelom... Solid Tumor | Total Body Irra... Total Body Irra... Cyclophosphamid... Mesna Cord Blood Infu... Busulfan Fludarabine Melphalan | 2 Months - 75 Years | University of Rochester | |
| Investigation of the Cylex® ImmuKnow® Assay | NCT00569842 | Leukemia Non-Hodgkin's L... Chronic Lymphoc... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... Aplastic Anemia Chronic Myeloge... | 18 Years - | Indiana University | ||
| Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure | NCT00895739 | Nonmalignant Ne... | alemtuzumab cyclosporine | 18 Years - | National Cancer Institute (NCI) | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload | NCT02833493 | Aplastic Anemia Dysmyelopoietic... Iron Overload | 18 Years - 80 Years | Peking Union Medical College Hospital | ||
| Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer | NCT00816413 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... Nonmalignant Ne... | cyclosporine mycophenolate m... pentostatin cytogenetic ana... fluorescence in... protein analysi... flow cytometry immunoenzyme te... laboratory biom... reduced-intensi... nonmyeloablativ... peripheral bloo... total-body irra... | 19 Years - 75 Years | University of Nebraska | |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | NCT06398457 | Hematologic Mal... Bone Marrow Tra... Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Multiple Myelom... Aplastic Anemia Lymphoma Non Hodgkin Lym... Hodgkin Lymphom... Chronic Myeloid... Myelofibrosis | Darzalex Faspro... JH-DSA Semi-Qua... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | NCT01500161 | Acute Myelogeno... Acute Lymphocyt... Chronic Lymphoc... Chronic Myeloge... Hodgkins Diseas... Non-Hodgkins Ly... Aplastic Anemia Multiple Myelom... Myelodysplastic... | Busulfan Clofarabine Fludarabine Melphalan Carmustine Etoposide Cytarabine | 18 Years - 65 Years | Texas Oncology Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
